Isocitrate dehydrogenase 1 and 2 mutations in gliomas

Journal of Neuroscience Research

Volumn 92, Issue 12, 2014, Pages 1611-1620

  Megova, Magdalena ^a   Drabek, Jiri ^a   Koudelakova, Vladimira ^a   Trojanec, Radek ^a   Kalita, Ondrej ^a   Hajduch, Marian ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

2 hydroxyglutarate; Glioma; IDH1; IDH2; Isocitrate dehydrogenase; Predictive marker; Prognostic marker

Indexed keywords

2 HYDROXYGLUTARIC ACID; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

CANCER PROGNOSIS; DNA METHYLATION; ENZYME ACTIVE SITE; ENZYME METABOLISM; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; MEDLINE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; SINGLE STRAND CONFORMATION POLYMORPHISM; WEB OF SCIENCE; BRAIN TUMOR; FACTUAL DATABASE; GENETICS; MUTATION; STATISTICS AND NUMERICAL DATA;

BRAIN NEOPLASMS; DATABASES, FACTUAL; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION;

EID: 84911986911     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23456     Document Type: Review

References (108)

1. Ahmadi R, Stockhammer F, Becker N, Hohlen K, Misch M, Christians A, Dictus C, Herold-Mende C, Capper D, Unterberg A, von Deimling A, Wick W, Hartmann C. 2012. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol 109:15-22.
2. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn PC, Futreal A, Tirabosco R, Flanagan AM. 2011a. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224:334-343.
3. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, McCarthy S, Fantin VR, Straley KS, Lobo S, Aston W, Green CL, Gale RE, Tirabosco R, Futreal A, Campbell P, Presneau N, Flanagan AM. 2011b. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 43:1262-1265.
4. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG, Sorensen AG. 2012. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 4:116ra4.
5. Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K. 2013. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126:267-276.
6. Badiali M, Gleize V, Paris S, Moi L, Elhouadani S, Arcella A, Morace R, Antonelli M, Buttarelli F, Figarella-Branger D, Kim YH, Ohgaki H, Mokhtari K, Sanson M, Giangaspero F. 2012. KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults. Brain Pathol 22:841-847.
7. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. 2008. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602.
8. Balss J, Pusch S, Beck AC, Herold-Mende C, Kramer A, Thiede C, Buckel W, Langhans CD, Okun JG, von Deimling A. 2012. Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. Acta Neuropathol 124:883-891.
9. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SK, Vogelstein B, Bigner D, Yan H, Papadopoulos N, Kinzler KW. 2011. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453-1455.
10. Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
11. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. 2009. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599-601.
12. Capper D, Sahm F, Hartmann C, Meyermann R, von DA, Schittenhelm J. 2010a. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 34:1199-1204.
13. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A. 2010b. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245-254.
14. Choi C, Ganji S, DeBerardinis R, Hatanpaa K, Rakheja D, Kovacs Z, Yang XL, Mashimo T, Raisanen J, Marin-Valencia I, Pascual J, Madden C, Mickey B, Malloy C, Bachoo R, Maher E. 2012. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18:624-629.
15. Dang L, White D, Gross S, Bennett B, Bittinger M, Driggers E, Fantin V, Jang H, Jin S, Keenan M, Marks K, Prins R, Ward P, Yen K, Liau L, Rabinowitz J, Cantley L, Thompson C, Vander Heiden M, Su S. 2009. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-744.
16. Duncan C, Barwick B, Jin G, Rago C, Kapoor-Vazirani P, Powell D, Chi JT, Bigner D, Vertino P, Yan H. 2012. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res 22:2339-2355.
17. Duncan R, Bazar L, Michelotti G, Tomonaga T, Krutzsch H, Avigan M, Levens D. 1994. A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev 8:465-480.
18. Felsberg J, Wolter M, Seul H, Friedensdorf B, Goppert M, Sabel M, Reifenberger G. 2010. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 119:501-507.
19. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Lowenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-567.
20. Fontebasso AM, Schwartzentruber J, Khuong-Quang DA, Liu XY, Sturm D, Korshunov A, Jones DT, Witt H, Kool M, Albrecht S, Fleming A, Hadjadj D, Busche S, Lepage P, Montpetit A, Staffa A, Gerges N, Zakrzewska M, Zakrzewski K, Liberski PP, Hauser P, Garami M, Klekner A, Bognar L, Zadeh G, Faury D, Pfister SM, Jabado N, Majewski J. 2013. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol 125:659-669.
21. Gilbert MR, Liu Y, Neltner J, Pu H, Morris A, Sunkara M, Pittman T, Kyprianou N, Horbinski C. 2014. Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol 127:221-233.
22. Gorlia T, Delattre JY, Brandes AA, Kros JM, Taphoorn MJ, Kouwenhoven MC, Bernsen HJ, Frenay M, Tijssen CC, Lacombe D, van den Bent MJ. 2013. New clinical, pathological, and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. Eur J Cancer 49:3477-3485.
23. Goze C, Bezzina C, Goze E, Rigau V, Maudelonde T, Bauchet L, Duffau H. 2012. 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. J Neurooncol 108:69-75.
24. Gravendeel LA, Kloosterhof NK, Bralten LB, van MR, Dubbink HJ, Dinjens W, Bleeker FE, Hoogenraad CC, Michiels E, Kros JM, van den Bent M Smitt, PA French, PJ. 2010. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat 31:E1186-E1199.
25. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken J, Wesseling P, Reifenberger G, von Deimling A. 2009. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol 118:469-474.
26. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A. 2010. Patients with IDH1 wild-type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707-718.
27. Holt SE, Shay JW. 1999. Role of telomerase in cellular proliferation and cancer. J Cell Physiol 180:10-18.
28. Horbinski C. 2013. What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol 125:621-636.
29. Horbinski C, Kofler J, Kelly L, Murdoch G, Nikiforova M. 2009. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 68:1319-1325.
30. Horbinski C, Kelly L, Nikiforov Y, Durso M, Nikiforova M. 2010. Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn 12:487-492.
31. Horbinski C, Kofler J, Yeaney G, Camelo-Piragua S, Venneti S, Louis D, Perry A, Murdoch G, Nikiforova M. 2011. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol 21:564-574.
32. Ichimura K, Pearson D, Kocialkowski S, Backlund L, Chan R, Jones D, Collins V. 2009. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neurooncology 11:341-347.
33. Jancik S, Drabek J, Berkovcova J, Xu YZ, Stankova M, Klein J, Kolek V, Skarda J, Tichy T, Grygarkova I, Radzioch D, Hajduch M. 2012. A comparison of direct sequencing, pyrosequencing, high resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas. J Exp Clin Cancer Res 31:79.
34. Jenkins R, Xiao Y, Sicotte H, Decker P, Kollmeyer T, Hansen H, Kosel M, Zheng S, Walsh K, Rice T, Bracci P, McCoy L, Smirnov I, Patoka J, Hsuang G, Wiemels J, Tihan T, Pico A, Prados M, Chang S, Berger M, Caron A, Fink S, Halder C, Rynearson A, Fridley B, Buckner J, O'Neill B, Giannini C, Lachance D, Wiencke J, Eckel-Passow J, Wrensch M. 2012. A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet 44:1122-1125.
35. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H. 2012. Frequent ATRX, CIC, FUBP1, and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709-722.
36. Jin G, Reitman Z, Spasojevic I, Batinic-Haberle I, Yang J, Schmidt-Kittler O, Bigner D, Yan H. 2011. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One 6.
37. Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez GY, He Y, McLendon RE, Bigner DD, Yan H. 2013. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res 73:496-501.
38. +-dependent isocitrate dehydrogenase. J Biol Chem 276:16168-16176.
39. Juratli TA, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, Soucek S, Schrock E, Schackert G, Krex D. 2012. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol 110:325-333.
40. Kanamori M, Kumabe T, Shibahara I, Saito R, Yamashita Y, Sonoda Y, Suzuki H, Watanabe M, Tominaga T. 2013. Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases. Brain Tumor Pathol 30:151-159.
41. Kaneko MK, Tian W, Takano S, Suzuki H, Sawa Y, Hozumi Y, Goto K, Yamazaki K, Kitanaka C, Kato Y. 2011. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem Biophys Res Commun 406:608-613.
42. Kaneko MK, Morita S, Tsujimoto Y, Yanagiya R, Nasu K, Sasaki H, Hozumi Y, Goto K, Natsume A, Watanabe M, Kumabe T, Takano S, Kato Y. 2013a. Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations. Biochem Biophys Res Commun 432:40-45.
43. Kaneko MK, Ogasawara S, Kato Y. 2013b. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations. Tohoku J Exp Med 230:103-109.
44. Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, Heguy A, Petrini JH, Chan TA, Huse JT. 2012. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3:1194-1203.
45. Kato Y, Kaneko MK. 2013. Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation. Biochem Biophys Res Commun 433:374-378.
46. Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD. 2009. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 390:547-551.
47. Kato Y, Natsume A, Kaneko MK. 2013. A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation. Biochem Biophys Res Commun 432:564-567.
48. Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon JE, Yan H, Bigner DD. 2014. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515-1525.
49. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawski R, Watanabe T, De GU, Kleihues P, Ohgaki H. 2010. Molecular classification of low-grade diffuse gliomas. Am J Pathol 177:2708-2714.
50. Klose RJ, Kallin EM, Zhang Y. 2006. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet 7:715-727.
51. Koivunen P, Lee S, Duncan C, Lopez G, Lu G, Ramkissoon S, Losman J, Joensuu P, Bergmann U, Gross S, Travins J, Weiss S, Looper R, Ligon K, Verhaak R, Yan H, Kaelin W. 2012. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483:484-488.
52. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C. 2009. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118:401-405.
53. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach J, Heese O, Reifenberger G, Weller M, Schackert G, German GN. 2007. Long-term survival with glioblastoma multiforme. Brain 130:2596-2606.
54. Labussiere M, Idbaih A, Wang XW, Marie Y, Boisselier B, Falet C, Paris S, Laffaire J, Carpentier C, Criniere E, Ducray F, El HS, Mokhtari K, Hoang-Xuan K, Delattre JY, Sanson M. 2010. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74:1886-1890.
55. Lass U, Neumann A, von Eckardstein K, Kiwit J, Stockhammer F, Horaczek J, Veelken J, Herold-Mende C, Jeuken J, von Deimling A, Mueller W. 2012. Clonal analysis in recurrent astrocytic, oligoastrocytic, and oligodendroglial tumors implicates IDH1-mutation as common tumor initiating event. PLoS One 7.
56. Lee CJ, Chan WI, Cheung M, Cheng YC, Appleby VJ, Orme AT, Scotting PJ. 2002. CIC, a member of a novel subfamily of the HMG-box superfamily, is transiently expressed in developing granule neurons. Brain Res Mol Brain Res 106:151-156.
57. Li S, Chou A, Chen W, Chen R, Deng Y, Phillips H, Selfridge J, Zurayk M, Lou J, Everson R, Wu KC, Faull K, Cloughesy T, Liau L, Lai A. 2013. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neurooncology 15:57-68.
58. Liu X, Wu G, Shan Y, Hartmann C, von DA, Xing M. 2013. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 12:1637-1638.
59. Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso A, Fleming A, Hadjadj D, Schwartzentruber J, Majewski J, Dong Z, Siegel P, Albrecht S, Croul S, Jones D, Kool M, Tonjes M, Reifenberger G, Faury D, Zadeh G, Pfister S, Jabado N. 2012. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615-625.
60. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley GS, Root DE, Ebert BL, Kaelin WG Jr. 2013. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339:1621-1625.
61. Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A, Scheithauer B, Kleihues P. 2007. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109.
62. Loussouarn D, Le Loupp AG, Frenel JS, Leclair F, von Deimling A, Aumont M, Martin S, Campone M, Denis M. 2012. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int J Oncol 40:2058-2062.
63. Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de LT, De S, Petrini JH, Sung PA, Jasin M, Rosenbluh J, Zwang Y, Weir BA, Hatton C, Ivanova E, Macconaill L, Hanna M, Hahn WC, Lue NF, Reddel RR, Jiao Y, Kinzler K, Vogelstein B, Papadopoulos N, Meeker AK. 2012. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 8:e1002772.
64. Lu C, Ward P, Kapoor G, Rohle D, Turcan S, Abdel-Wahab O, Edwards C, Khanin R, Figueroa M, Melnick A, Wellen K, O'Rourke D, Berger S, Chan T, Levine R, Mellinghoff I, Thompson C. 2012. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474-478.
65. Lv S, Teugels E, Sadones J, Quartier E, Huylebrouck M, Du Four S, Le Mercier M, De Witte O, Salmon I, Michotte A, De Greve J, Neyns B. 2011. Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma. Anticancer Res 31:4457-4463.
66. McDowell TL, Gibbons RJ, Sutherland H, O'Rourke DM, Bickmore WA, Pombo A, Turley H, Gatter K, Picketts DJ, Buckle VJ, Chapman L, Rhodes D, Higgs DR. 1999. Localization of a putative transcriptional regulator (ATRX) at pericentromeric heterochromatin and the short arms of acrocentric chromosomes. Proc Natl Acad Sci U S A 96:13983-13988.
67. Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D. 2011. IDH1 and IDH2 mutations, immunohistochemistry, and associations in a series of brain tumors. J. Neurooncol 105:345-357.
68. Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K, Wang XW, Loundou A, Chapon F, Pineau S, Ouafik L, Chinot O, Figarella-Branger D. 2010. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719-729.
69. Meyer J, Pusch S, Balss J, Capper D, Mueller W, Christians A, Hartmann C, von Deimling A. 2010. PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol 20:298-300.
70. Mohrenz IV, Antonietti P, Pusch S, Capper D, Balss J, Voigt S, Weissert S, Mukrowsky A, Frank J, Senft C, Seifert V, von DA, Kogel D. 2013. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis 18:1416-1425.
71. Noushmehr H, Weisenberger D, Diefes K, Phillips H, Pujara K, Berman B, Pan F, Pelloski C, Sulman E, Bhat K, Verhaak R, Hoadley K, Hayes D, Perou C, Schmidt H, Ding L, Wilson R, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope L, Buckley J, Herman J, Baylin S, Laird P, Aldape K, Cancer Genome Atlas Research Network. 2010. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522.
72. Ohgaki H, Kleihues P. 2005. Epidemiology and etiology of gliomas. Acta Neuropathol 109:93-108.
73. Pang B, Durso MB, Hamilton RL, Nikiforova MN. 2013. A novel COLD-PCR/FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas. Diagn Mol Pathol 22:28-34.
74. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch N, Maiorka P, Baeza N, Pisani P, Yonekawa Y, Yasargil M, Lutolf U, Kleihues P. 2004. Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892-6899.
75. Parsons D, Jones S, Zhang X, Lin J, Leary R, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia G, Olivi A, McLendon R, Rasheed B, Keir S, Nikolskaya T, Nikolsky Y, Busam D, Tekleab H, Diaz L, Hartigan J, Smith D, Strausberg R, Marie S, Shinjo S, Yan H, Riggins G, Bigner D, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu V, Kinzler K. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812.
76. Peng Z, Haitao X, Pin C, Qing Y, Lin Z, Peng Z, Aihua G, Isaac Y. 2013. IDH1/IDH2 Mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One 8.
77. Perizzolo M, Winkfein B, Hui S, Krulicki W, Chan J, Demetrick D. 2012. IDH mutation detection in formalin-fixed paraffin-embedded gliomas using multiplex PCR and single-base extension. Brain Pathol 22:619-624.
78. Pietrak B, Zhao H, Qi H, Quinn C, Gao E, Boyer J, Concha N, Brown K, Duraiswami C, Wooster R, Sweitzer S, Schwartz B. 2011. A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of alpha-HG. Biochemistry 50:4804-4812.
79. Pirozzi CJ, Reitman ZJ, Yan H. 2013. Releasing the block: setting differentiation free with mutant IDH inhibitors. Cancer Cell 23:570-572.
80. Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Lyons-Weiler MA, LaFramboise WA, Burger PC, Brat DJ, Rosenblum MK, Holmes EJ, Zhou T, Jakacki RI. 2011. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst 27:87-94.
81. Pusch S, Sahm F, Meyer J, Mittelbronn M, Hartmann C, von Deimling A. 2011. Glioma IDH1 mutation patterns off the beaten track. Neuropathol Appl Neurobiol 37:428-430.
82. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum M, Liu W, Biller S, Su S, Brennan C, Chan T, Graeber T, Yen K, Mellinghoff I. 2013. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:626-630.
83. Sahm F, Capper D, Pusch S, Balss J, Koch A, Langhans CD, Okun JG, von Deimling A. 2012a. Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry. Brain Pathol 22:26-31.
84. Sahm F, Koelsche C, Meyer J, Pusch S, Lindenberg K, Mueller W, Herold-Mende C, von Deimling A, Hartmann C. 2012b. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 123:853-860.
85. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A, Harris IS, Holmes R, Wakeham A, Haight J, You-Ten A, Li WY, Schalm S, Su SM, Virtanen C, Reifenberger G, Ohashi PS, Barber DL, Figueroa ME, Melnick A, Zuniga-Pflucker JC, Mak TW. 2012. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488:656-659.
86. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jager N, Rausch T, Ryzhova M, Korbel JO, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann MU, Scheurlen W, Pekrun A, Fruhwald MC, Roggendorf W, Kramm C, Durken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel P, Kulozik AE, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von DA, Ichimura K, Collins VP, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister SM, Jabado N. 2012. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226-231.
87. Seiz M, Tuettenberg J, Meyer J, Essig M, Schmieder K, Mawrin C, von Deimling A, Hartmann C. 2010. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol 120:261-267.
88. Shibahara I, Sonoda Y, Kanamori M, Saito R, Yamashita Y, Kumabe T, Watanabe M, Suzuki H, Kato S, Ishioka C, Tominaga T. 2012. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol 17:551-561.
89. SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, LanXiao W, Fei Y. 2012. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 103:269-273.
90. Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T. 2009. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100:1996-1998.
91. Tonjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, Pleier SV, Bai AH, Karra D, Piro RM, Felsberg J, Addington A, Lemke D, Weibrecht I, Hovestadt V, Rolli CG, Campos B, Turcan S, Sturm D, Witt H, Chan TA, Herold-Mende C, Kemkemer R, Konig R, Schmidt K, Hull WE, Pfister SM, Jugold M, Hutson SM, Plass C, Okun JG, Reifenberger G, Lichter P, Radlwimmer B. 2013. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med 19:901-908.
92. Turcan S, Rohle D, Goenka A, Walsh L, Fang F, Yilmaz E, Campos C, Fabius A, Lu C, Ward P, Thompson C, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris L, Huse J, Mellinghoff I, Chan T. 2012. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479-483.
93. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van MR, Kros JM, Dinjens WN, Gorlia T, Sanson M. 2010. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597-1604.
94. van den Bent MJ, Hartmann C, Preusser M, Strobel T, Dubbink Hendrikus J., Kros JM, von Deimling A, Boisselier B, Sanson M, Halling KC, Diefes KL, Aldape K, Giannini C. 2013. Interlaboratory comparison of IDH mutation detection. J Neurooncol 112:173-178.
95. Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M, Miller C, Ding L, Golub T, Mesirov J, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir B, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler H, Hodgson J, James C, Sarkaria J, Brennan C, Kahn A, Spellman P, Wilson R, Speed T, Gray J, Meyerson M, Getz G, Perou C, Hayes D, Cancer Genome Atlas Research Network. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110.
96. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, Yang H, Gross S, Artin E, Saada V, Mylonas E, Quivoron C, Popovici-Muller J, Saunders JO, Salituro FG, Yan S, Murray S, Wei W, Gao Y, Dang L, Dorsch M, Agresta S, Schenkein DP, Biller SA, Su SM, de BS, Yen KE. 2013. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340:622-626.
97. Ward P, Cross J, Lu C, Weigert O, Abel-Wahab O, Levine R, Weinstock D, Sharp K, Thompson C. 2012. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene 31:2491-2498.
98. Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK, Thompson CB. 2013. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 288:3804-3815.
99. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. 2009. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149-1153.
100. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M. 2009. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874-5880.
101. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister S, Platten M, Weller M, Wick W. 2013. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443-451.
102. Williams SC, Karajannis MA, Chiriboga L, Golfinos JG, von DA, Zagzag D. 2011. R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1alpha upregulation in adult glioma. Acta Neuropathol 121:279-281.
103. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu Lx, Jiang Wq, Liu J, Zhang Jy, Wang B, Frye S, Zhang Y, Xu Yh, Lei Qy, Guan KL, Zhao Sm, Xiong Y. 2011. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17-30.
104. Xu X, Zhao J, Xu Z, Peng B, Huang Q, Arnold E, Ding J. 2004. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem 279:33946-33957.
105. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. 2009. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773.
106. Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu HG, Ling ZQ, Ye D, Guan KL, Xiong Y. 2013. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 32:663-669.
107. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, Li H, Louis DN, Maslova A, Moore R, Moradian A, Mungall KL, Perizzolo M, Qian J, Roldan G, Smith EE, Tamura-Wells J, Thiessen N, Varhol R, Weiss S, Wu W, Young S, Zhao Y, Mungall AJ, Jones SJ, Morin GB, Chan JA, Cairncross JG, Marra MA. 2012. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226:7-16.
108. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y. 2009. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324:261-265.